COVID-19 - Professional Rapid Diagnostic Solutions
Products:
1. Covid-19 tests (Antigen tests/Antibody tests after vaccination)
2. Fertility Tests
3. Drug of Abuse Tests
4. Infectious diseases (Flu/Dengue/Malaria, etc.)
4. Test items for cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor and other diseases.
After the outbreak of COVID-19, our company actively participated in anti-epidemic cause around the globe, providing COVID-19 quick test solution, including COVID-19 antibody test, antigen test and neutralizing antibody test, which can be widely used in large area screening and professional medical detection.
Our Covid-19 detection reagent is one of the first approved products by National Medical Products Association (former name SFDA)in China and approved by CE. At present, our Covid-19 detection products have covered more than 90 countries in Europe, Asia, Latin America, etc.
Our Covid-19 detection reagent is one of the first approved products by National Medical Products Association(former name SFDA)in China and also approved by CE. We have also received a letter of thanks from the Ministry of Science and Technology of the people's Republic of China for its outstanding contribution to the emergency prevention and control of epidemic situation. Founded in 1992, our company focuses on innovative research and development of in vitro diagnostic products and medical services. It is the leading enterprise in the field of POCT (Point of Care Test) in China, providing professional rapid diagnostic solutions for more than 140 countries and regions around the world. We are also getting the government approval of COVID-19 self test in Germany in coming weeks.
In recent years, our company has built a global "Ecosystem" and expanded the global coverage of products, technologies and channels by setting joint innovation bases, joint operation centers, and cross-border mergers and acquisitions.
The company has established research and development center in San Diego and branch office in Chicago.
Besides, we invested in factories in Asia, South America, Africa and the common wealth of independent states to build a global manufacturing system that helps reduce the delivery time and cost.
The company has set up more than 20 subsidiaries worldwide, providing products, solutions, and technical support to customers in more than 140 regions and countries.
Now we have plan to develop business opportunity in Israel. For example, we understand that the vaccine shot rates in Israel is very high , so our neutralizing antibody test can test whether the shot gets effective and provides protection, which may suits the situation in Israel well.
Key Advantages: We are the first public POCT (point of care testing) company in China, providing professional rapid diagnostic solutions for more than 140 countries and regions around the world. Continuous innovation drives us forward. Wondfo has developed “Nine Technology Platforms” which include 300+ clinical test items and has served 20,000+ medical institutions.
The price of our products are competitive in the market.
Our quality management system strictly complies with international standards and regulations.
We are open for discussion and ideas.
Our business partners worldwide are: UN, WHO, Bill Gates Foundation, IBM, Abbott, Johnson & Johnson, Biocartis, iCubate, SIEMENS, AstraZeneca, illumine, sysmex.
End customers: Watsons, Rossmann, Local Hospitals, Local Pharmacies.
Potential Partners: Medical Devices bidding agents/Representatives from ministry of health or other public health related government departments.
looking forward to hearing from you.
Company Info:
Year of Establishment: 1992
No. of Employees: +3000